MedTrace Logo

Reduction of IgE Antibody in Human Allergic Subjects

NCT01280149 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-08-21

No results posted yet for this study

Summary

The purpose of this study is to determine whether a neuropeptide, substance P, when injected along with an allergen, such as ragweed, can reduce allergic reactivity.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

BIOLOGICAL

substance P

injections of substance P and low dose allergen or placebo

BIOLOGICAL

substance P injections

injections of substance P for 8 weeks

Sponsors & Collaborators

Principal Investigators

  • Paul A Greenberger, M.D. · Northwestern University Feinberg School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2017-06-20
Completion
2017-06-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01280149 on ClinicalTrials.gov